1. Veracruz N., Hameed B., Saab S., Wong R.J. The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers. J Clin Exp Hepatol. 2021;11(1):45-81. doi: 10.1016/j.jceh.2020.04.018.
2. Simon T.G., Roelstraete B., Hagström H., Sundström J., Ludvigsson J.F. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71(9):1867-1875.. doi: 10.1136/gutjnl-2021-325724.
3. Pais R., Giral P., Khan J.F., Rosenbaum D., Housset C., Poynard T., Ratziu V.; LIDO Study Group. Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol. 2016;65(1):95-102. doi: 10.1016/j.jhep.2016.02.023.
4. Tang A.S.P., Chan K.E., Quek J., Xiao J., Tay P., Teng M., Lee K.S., Lin S.Y., Myint M.Z., Tan B., Sharma V.K., Tan D.J.H., Lim W.H., Kaewdech A., Huang D., Chew N.W., Siddiqui M.S., Sanyal A.J., Muthiah M., Ng C.H. Non-alcoholic fatty liver disease increases Risk of Carotid Atherosclerosis and Ischemic Stroke. An Updated Meta-Analysis with 135,602 Individuals. Clin Mol Hepatol. 2022;28(3):483-496. doi: 10.3350/cmh.2021.0406.
5. Генкель В.В., Кузнецова А.С., Лебедев Е.В., Шапошник И.И. Факторы, связанные с эхогенностью атеросклеротических бляшек, у пациентов в возрасте 40-64 лет с каротидным атеросклерозом. Кардиология. 2021;61(6):35-40. doi: 10.18087/cardio.2021.6.n1536.
6. Cloutier G., Cardinal M.R., Ju Y., Giroux M.F., Lanthier S., Soulez G. Carotid Plaque Vulnerability Assessment Using Ultrasound Elastography and Echogenicity Analysis. AJR Am J Roentgenol. 2018;211(4):847-855. doi: 10.2214/AJR.17.192
7. Loomba R., Wong R., Fraysse J., Shreay S., Li S., Harrison S., Gordon S.C. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther. 2020;51(11):1149-1159. doi: 10.1111/apt.15679.
8. Брель Н.К., Груздева О.В., Коков А.Н., Масенко В.Л., Дылева Ю.А., Белик Е.В., Барбараш О.Л. Взаимосвязь висцерального ожирения и коронарного кальциноза при ишемической болезни сердца. Терапевтический архив. 2021;93(12):1428-1434. doi: 10.26442/00403660.2021.12.201277
9. Гарбузенко Д.В., Белов Д.В. Неалкогольная жировая болезнь печени как независимый фактор кардиометаболического риска сердечно-сосудистых заболеваний. Экспериментальная и клиническая гастроэнтерология. 2021;10 (194):22-34. doi: 10.31146/1682-8658-ecg-194-10-22-34
10. Lauridsen B.K., Stender S., Kristensen T.S., Kofoed K.F., Køber L., Nordestgaard B.G., Tybjærg-Hansen A. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. Eur Heart J. 2018;39(5):385-393. doi: 10.1093/eurheartj/ehx662.
11. Chandrasekharan K., Alazawi W. Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy? Front Pharmacol. 2020;10:1413. doi: 10.3389/fphar.2019.01413.
12. Wu M., Zha M., Lv Q., Xie Y., Yuan K., Zhang X., Liu X. Non-alcoholic fatty liver disease and stroke: A Mendelian randomization study. Eur J Neurol. 2022;29(5):1534-1537. doi: 10.1111/ene.15277.
13. Chiriac S., Stanciu C., Girleanu I., Cojocariu C., Sfarti C., Singeap A.M., Cuciureanu T., Huiban L., Muzica C.M., Zenovia S., Nastasa R., Trifan A. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Can J Gastroenterol Hepatol. 2021;2021:6696857. doi: 10.1155/2021/6696857.
14. Zhan R., Qi R., Huang S., Lu Y., Wang X., Jiang J., Ruan X., Song A. The correlation between hepatic fat fraction evaluated by dual-energy computed tomography and high-risk coronary plaques in patients with non-alcoholic fatty liver disease. Jpn J Radiol. 2021;39(8):763-773. doi: 10.1007/s11604-021-01113-9.
15. Park H.E., Lee H., Choi S.Y., Kwak M.S., Yang J.I., Yim J.Y., Chung G.E. Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter. J Gastroenterol. 2019;54(3):271-280. doi: 10.1007/s00535-018-1516-5.
16. Kweon Y.N., Ko H.J., Kim A.S., Choi H.I., Song J.E., Park J.Y., Kim S.M., Hong H.E., Min K.J. Prediction of Cardiovascular Risk Using Nonalcoholic Fatty Liver Disease Scoring Systems. Healthcare (Basel). 2021;9(7):899. doi: 10.3390/healthcare9070899.
17. Johnson S.I., Fort D., Shortt K.J., Therapondos G., Galliano G.E., Nguyen T., Bluth E.I. Ultrasound Stratification of Hepatic Steatosis Using Hepatorenal Index. Diagnostics (Basel). 2021;11(8):1443. doi: 10.3390/diagnostics11081443.
18. Sprynger M., Rigo F., Moonen M., Aboyans V., Edvardsen T., de Alcantara M.L., Brodmann M., Naka K.K., Kownator S., Simova I., Vlachopoulos C., Wautrecht J.C., Lancellotti P.; EACVI Scientific Documents Committee. Focus on echovascular imaging assessment of arterial disease: complement to the ESC guidelines (PARTIM 1) in collaboration with the Working Group on Aorta and Peripheral Vascular Diseases. Eur Heart J Cardiovasc Imaging. 2018;19(11):1195-1221. doi: 10.1093/ehjci/jey103.
19. Marshall R.H., Eissa M., Bluth E.I., Gulotta P.M., Davis N.K. Hepatorenal index as an accurate, simple, and effective tool in screening for steatosis. AJR Am J Roentgenol. 2012;199(5):997-1002. doi: 10.2214/AJR.11.6677.
20. Tanpowpong N., Panichyawat S. Comparison of sonographic hepatorenal ratio and the degree of hepatic steatosis in magnetic resonance imaging-proton density fat fraction. J Ultrason. 2020;20(82):e169-e175. doi: 10.15557/JoU.2020.0028.
21. Hamaguchi M., Kojima T., Itoh Y., Harano Y., Fujii K., Nakajima T., Kato T., Takeda N., Okuda J., Ida K., Kawahito Y., Yoshikawa T., Okanoue T. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102(12):2708-15. doi: 10.1111/j.1572-0241.2007.01526.x.
22. Martín-Rodríguez J.L., Arrebola J.P., Jiménez-Moleón J.J., Olea N., González-Calvin J.L. Sonographic quantification of a hepato-renal index for the assessment of hepatic steatosis in comparison with 3T proton magnetic resonance spectroscopy. Eur J Gastroenterol Hepatol. 2014;26(1):88-94. doi: 10.1097/MEG.0b013e3283650650.
23. Hsiao C.C., Teng P.H., Wu Y.J., Shen Y.W., Mar G.Y., Wu F.Z. Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis. BMC Cardiovasc Disord. 2021;19;21(1):244. doi: 10.1186/s12872-021-02060-z.
24. Hsu P.F., Wang Y.W., Lin C.C., Wang Y.J., Ding Y.Z., Liou T.L., Huang S.S., Lu T.M., Chan W.L., Lin S.J., Leu H.B. The association of the steatosis severity in fatty liver disease with coronary plaque pattern in general population. Liver Int. 2021;41(1):81-90. doi: 10.1111/liv.14637.